NASDAQ$RARE
Ultragenyx Pharmaceutical Inc. · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Ultragenyx reported strong financial results with total revenue of $36.3 million and maintained full year 2020 financial guidance.
Ultragenyx reported first quarter 2020 financial results, with total revenue of $36.3 million. The company maintains full year 2020 guidance based on COVID-19 impact to date. The FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track to be completed in the coming months.
- Total revenue for the first quarter of 2020 was $36.3 million.
- Crysvita revenue in Ultragenyx territories was $28.8 million.
- The company maintains full year 2020 guidance.
- FDA reviews for Crysvita for TIO and UX007 for LC-FAOD are on track.
Headline financials
Revenue & EPS history
Ultragenyx · Revenue · Quarterly
$36.3M
Revenue by segment
Ultragenyx · $32.2M total across 2 segments · Q1 2020
- Crysvita Revenue$28.8M—89.4%
- Mepsevii Revenue$3.4M—10.6%
Forward guidance
The company currently maintains the guidance range for 2020 Crysvita revenue in the Ultragenyx territories to be between $125.0 million and $140.0 million, although it continues to monitor the COVID-19 pandemic situation. The company also expects a more than 20 percent reduction in net cash burn in 2020 compared to 2019 due to a combination of financial discipline in spending with flattening operating expense growth, combined with a significant anticipated growth in revenue.
Tailwinds
- Crysvita revenue guidance maintained between $125.0 million and $140.0 million.
- Expects a more than 20% reduction in net cash burn in 2020 compared to 2019.
- Financial discipline in spending.
- Flattening operating expense growth.
- Significant anticipated growth in revenue.
Headwinds
- Continues to monitor the COVID-19 pandemic situation.
- Potential delays in clinical trials due to COVID-19
- Uncertainties related to insurance coverage and reimbursement approval for the company’s products
- Manufacturing risks
- Smaller than anticipated market opportunities for the company’s products and product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-1.2%
Avg return
Earnings day
-0.5%
Avg return
5 days after
+0.1%
Avg return
30 days after
42%
20 / 48 earnings
Positive
+14.7%
Q1 2015
Best reaction
-18.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | +5.2% | -12.5% | |
| Q4 2025 | -12.7% | -13.0% | -9.2% | |
| Q3 2025 | -1.5% | -1.6% | +12.1% | |
| Q1 2025 | -4.8% | +2.9% | +6.0% | |
| Q4 2024 | -2.4% | +1.8% | -9.6% | |
| Q3 2024 | -1.1% | -1.4% | -7.3% | |
| Q2 2024 | +12.1% | +10.6% | +26.1% | |
| Q1 2024 | -1.3% | -3.1% | -7.3% | |
| Q4 2023 | +7.1% | +4.8% | +3.7% | |
| Q3 2023 | +7.7% | +5.7% | +11.4% | |
| Q2 2023 | -11.1% | -16.9% | -10.8% | |
| Q1 2023 | +9.0% | +8.6% | +17.4% | |
| Q4 2022 | +10.2% | +2.9% | -12.8% | |
| Q3 2022 | -9.0% | -16.4% | -4.2% | |
| Q2 2022 | +4.9% | +0.9% | -2.6% | |
| Q1 2022 | -18.9% | -24.5% | -27.5% | |
| Q4 2021 | -2.5% | -1.6% | -12.5% | |
| Q3 2021 | +0.0% | -3.1% | -8.0% | |
| Q2 2021 | +4.9% | +10.9% | +24.8% | |
| Q1 2021 | -0.5% | +7.5% | -11.4% | |
| Q4 2020 | -10.1% | -13.7% | -24.1% | |
| Q3 2020 | +4.1% | +10.1% | +31.3% | |
| Q2 2020 | +2.5% | +10.4% | +12.4% | |
| Q1 2020 | -2.4% | +4.1% | +8.1% | |
| Q4 2019 | -2.8% | -2.8% | -31.1% | |
| Q3 2019 | -7.9% | -4.6% | +5.0% | |
| Q2 2019 | -7.6% | -3.6% | -9.6% | |
| Q1 2019 | -8.0% | -5.7% | -15.4% | |
| Q4 2018 | +6.8% | +5.6% | +21.9% | |
| Q3 2018 | +0.9% | -3.0% | -6.4% | |
| Q2 2018 | -9.5% | -2.5% | +6.8% | |
| Q1 2018 | +6.1% | +17.7% | +42.3% | |
| Q4 2017 | -1.7% | +1.6% | +9.0% | |
| Q3 2017 | +3.2% | -5.2% | +7.7% | |
| Q2 2017 | -5.4% | -10.6% | -27.4% | |
| Q1 2017 | +2.0% | +2.5% | -5.1% | |
| Q4 2016 | +0.2% | +0.2% | +10.2% | |
| Q2 2016 | -2.2% | +0.2% | +2.5% | |
| Q1 2016 | +0.6% | — | — | |
| Q4 2015 | -0.7% | — | — | |
| Q3 2015 | -6.1% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | +14.7% | — | — | |
| Q4 2014 | -7.2% | — | — | |
| Q3 2014 | -4.2% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q4 2013 | -8.4% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro